We are engineering
the end of autoimmunity.
“Make impossible what is today inevitable.”
Eradicate autoimmune diabetes as a chronic human disease within the next clinical generation — restoring immune tolerance through in situ transdifferentiation guided by quantum computing.
We are not pursuing a better treatment. We are pursuing the removal of the diagnostic category. Every experiment, every line of code, every allocated qubit exists under that single criterion. If a decision does not move us toward that end, it does not enter the protocol.
The four pillars of NucleosX
Biology as code
Every biological hypothesis is a versioned, auditable, reproducible artifact — single-cell evidence under source control.
Anti-hallucination
No claim is published without traceability to primary literature. Continuous audit under the NucleosX Protocol.
In situ transdifferentiation
We reprogram cells without ex vivo extraction. Project Quimera V5 turns patient physiology into the therapeutic laboratory.
Quantum-majority compute
We invest the majority of our research capital in quantum capacity — because human biology is, at the fundamental scale, a quantum system.
Philosophy
NucleosX was born from a simple observation: medicine treats autoimmunity as fate. We treat it as a solvable computational engineering problem.
We operate under three inseparable disciplines: single-cell biology, quantum computing, and epistemic audit. None of the three alone is sufficient. Their combination — versioned, reproducible, falsifiable — is what we call the NucleosX Protocol.
We believe the 21st century will be defined by organizations capable of treating biological knowledge as production code: tested, reviewed, rollbackable. That is the only honest way to promise a cure.
Setor Médico Hospitalar Norte, Centro Clínico Cleo Octavio, Asa Norte, Brasília — DF, Brazil
Medical director: Dr. Matheus Jose Alves · CRM-DF 34647
Capital for the end of autoimmunity.
NucleosX is open to strategic foreign investment aligned with our century-horizon thesis. We work with funds, family offices and sovereign vehicles that understand deep-tech biology, quantum infrastructure and long-cycle clinical outcomes. Proposals, term-sheets and diligence requests:
Response SLA · 5 business days · São Paulo / Brazil